The Potential Therapeutic Prospect of PANoptosis in Heart Failure
Yunfeng Jia,Yayi Liu,Yiming Zuo,Junping Zhang,Yanyang Li,Xuezheng Liu,Shichao Lv
DOI: https://doi.org/10.2147/jir.s485901
IF: 4.5
2024-11-27
Journal of Inflammation Research
Abstract:Yunfeng Jia, 1 Yayi Liu, 1 Yiming Zuo, 1 Junping Zhang, 1 Yanyang Li, 2, 3 Xuezheng Liu, 1 Shichao Lv 1 1 Department of Geriatrics, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine (National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion), Tianjin, 300381, People's Republic of China; 2 Department of Integrated Traditional and Western Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, People's Republic of China; 3 Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, People's Republic of China Correspondence: Shichao Lv; Xuezheng Liu, Department of Geriatrics, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No. 88 Changling Street, Xiqing District, Tianjin, 300193, People's Republic of China, Email ; Heart failure (HF) represents a serious manifestation or advanced stage of various cardiac diseases. HF continues to impose a significant global disease burden, characterized by high rates of hospitalization and fatality. Furthermore, the pathogenesis and pathophysiological processes underlying HF remain incompletely understood, complicating its prevention and treatment strategies. One significant pathophysiological mechanism associated with HF is the systemic inflammatory response. PANoptosis, a novel mode of inflammatory cell death, has been extensively studied in the context of infectious diseases, neurodegenerative disorders, cancers, and other inflammatory conditions. Recent investigations have revealed that PANoptosis-related genes are markedly dysregulated in HF specimens. Consequently, the PANoptosis-mediated inflammatory response may represent a potential mechanism and therapeutic target for HF. This paper conducts a comprehensive analysis of the molecular pathways that drive PANoptosis. We discuss its role and potential therapeutic targets in HF, thereby providing valuable insights for clinical treatment and the development of novel therapies. Keywords: PANoptosis, pyroptosis, apoptosis, necroptosis, cell death, heart failure HF is an extremely complicated, life-threatening clinical illness characterized by aberrant heart anatomy or function. This condition results in impaired filling of the ventricular and ejection function, as well as the heart's inability to satisfy the systemic circulatory demands. It is the final stage of most cardiovascular diseases. 1 With the progress of population aging, the life expectancy extension, and the improvement of the survival rate of acute myocardial infarction, the prevalence of HF is growing year after year. Upon an investigation of the burden of HF in 195 different nations and regions, it was discovered that the total amount of people suffering HF globally is approximately 33.5 million to 64.3 million. 2 The incidence of HF in Europe is about 3 in 1000 among all age groups and can reach 5 in 1000 among adults. 3,4 Furthermore, HF, with its high rates of hospitalization and mortality, constitutes a considerable global illness burden. According to cohort research conducted between 2000 and 2010, the one-year and 5-years rates of mortality for HF were 20% and 53%, consequently, with an average hospitalization rate of 1.34 per person-year. 5 Despite tremendous breakthroughs in the pharmaceutical and physical therapy of HF after more than half a century, patient clinical outcomes and quality of life remain unsatisfactory, representing a major public health concern. Consequently, identifying new targets for the treatment of HF and developing a more comprehensive and effective strategy for its management remain our current and future challenges. As a chronic and spontaneously progressive disease, HF is characterized by a systemic proinflammatory state. 6,7 An excessive inflammatory response can exacerbate HF, while elevated levels of inflammatory factors are indicative of poor prognosis in patients. The persistent expression of these inflammatory factors continuously activates the inflammatory cascade, resulting in cardiomyocyte death, cardiac fibrosis, and impaired ventricular remodeling. 8,9 This cascade ultimately leads to both diastolic and systolic dysfunction of the heart, contributing to the onset and progression of HF. Therefore, intervening in the inflammatory state associated with HF and regulating cardiomyocyte death to prevent cardiac fibrosis and poor ventricular remodeling may represent a promising therapeutic strategy for the prevention and treatment of this condition. The inflammatory response mediated by cardiomyocyte death is the key link of myocardial injury and adverse ventricular remodeling. 10,11 Apoptosis, pyrop -Abstract Truncated-
immunology